BioPharma Reporter

JANUARY 25, 2021

An in vitro study shows Moderna's existing mRNA COVID-19 vaccine provides protection against strains that have emerged from South Africa and the UK. But it does suggest reduced protection against the South Africa strain, and so the company is also developing a new booster designed for maximum efficacy against this variant.

Vaccination 105

Vaccination Vaccine In-Vitro Development 105

Pharmaceutical Technology

OCTOBER 5, 2022

Patients with end-stage CLL have yet to benefit from an approved cell therapy, despite many developers initially trialling autologous CAR-T agents such as Yescarta and Kymriah in CLL during Phase I studies. Although CLL is a B-cell malignancy, patients also suffer from dysfunctional T-cells that exhibit an exhausted phenotype.

In-Vitro 279

In-Vitro In-Vivo Sales Clinical Trials 279

Pharmaceutical Technology

SEPTEMBER 22, 2022

Abpro has entered a strategic collaboration with Celltrion for the global development and commercialisation of the former's antibody therapy, a t-cell engager known as ABP 102. The cancer molecule will be developed for treating patients with HER2+ cancer, including gastric, pancreatic and breast cancer.

Antibody 130

Antibody Development Bioinformatics In-Vitro 130

Pharmaceutical Technology

MAY 4, 2023

The approval allows KALYDECO to be used in infants who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to the therapy, on the basis of clinical and/or in vitro assay results. This cohort showed a safety profile identical to that found in older children and adults.

In-Vitro 246

In-Vitro Genetic Disease Medicine Genetics 246

Pharmaceutical Technology

APRIL 14, 2023

The company and the researchers, with Professor Krishanu Saha as principal investigator (PI) and Dr Christian Capitini as co-PI, will develop a GD2 CAR T-cell therapeutic candidate to treat neuroblastoma, a cancer type that generally affects young children. Topic sponsors are not involved in the creation of editorial content.

In-Vivo 264

In-Vivo Gene Therapy In-Vitro Engineer 264

Pharmaceutical Technology

JANUARY 4, 2023

A synergistic activity was also observed between the anti-Gremlin1 antibody and enzalutamide against castration-resistant prostate cancer models derived from patients in vitro and in vivo. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242

Pharmaceutical Technology

NOVEMBER 9, 2022

ProPhase Labs’ wholly owned subsidiary ProPhase BioPharma has entered a two-year collaboration agreement with Dana-Farber Cancer Institute for further research and development of Linebacker-1 (LB-1). LB-1 will be given along with chemotherapy agents in-vitro, in various cell lines, and in-vivo subcutaneous mouse tumour models in the project.

In-Vivo 130

In-Vivo Development In-Vitro Scientist 130

Pharmaceutical Technology

NOVEMBER 10, 2022

NRG Therapeutics has raised Series A funds worth $18.3m (£16m) to progress the development of mitochondrial therapeutics to treat neurodegenerative ailments such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS). This could possibly stop or substantially slow down disease progression in Parkinson’s or ALS patients.

Development 130

Development In-Vitro Clinical Development Medicine 130

World of DTC Marketing

JULY 12, 2021

According to a report on CNN.com “Pfizer said it is seeing waning immunity from its coronavirus vaccine and says it is picking up its efforts to develop a booster dose that will protect people from variants.” SUMMARY: Pfizer says it has data on waning immunity from their COVID vaccine. The FDA and CDC say “not so fast.”

Vaccination 292

Vaccination Vaccine In-Vitro Doctor 292

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

XTalks

NOVEMBER 25, 2024

XTALKS WEBINAR: Enhance Early Biomarker Discovery: Translating In Vitro and In Vivo Multi-Omics Oncology Data Live and On-Demand: Thursday, January 16, 2025, at 11am EST (4pm GMT/UK) Register for this free webinar to learn how to harness the full potential of multi-omics data and advanced patient models to drive early biomarker discovery.

In-Vivo 105

In-Vivo FDA Approval In-Vitro Drugs 105

BioPharma Reporter

JANUARY 28, 2021

In vitro studies found the Pfizer/BioNTech COVID-19 vaccine elicits antibodies against both the UK and South African virus strains.

In-Vitro 119

In-Vitro Vaccination Vaccine Antibody 119

Pharma Mirror

AUGUST 30, 2022

The testing facility, located in North Carolina, provides supportive technology at no cost allowing companies to test and prove their cell-based products at various stages of development. By eliminating the fluctuations and suboptimal transients caused by.

Medicine 130

Medicine In-Vitro Production Manufacturing 130

Pharma Mirror

FEBRUARY 18, 2021

Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc. Capable of delivering any FDA approved.

Drug Delivery 130

Drug Delivery In-Vivo In-Vitro Drugs 130

XTalks

MARCH 1, 2021

The study is part of a broad development plan to assess the durability of the immunogenic responses elicited by its vaccine and the emergence of new SARS-CoV-2 variants. The study will be a part of current Phase I, II and III trials. The third booster will be given to participants from the Phase I study in the US.

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

Medical Xpress

JANUARY 23, 2023

Researchers have developed a new tool and technique that uses "vortex ultrasound"—a sort of ultrasonic tornado—to break down blood clots in the brain. The new approach worked more quickly than existing techniques to eliminate clots formed in an in vitro model of cerebral venous sinus thrombosis (CVST).

In-Vitro 97

In-Vitro Development Research Cardiology 97

pharmaphorum

SEPTEMBER 29, 2022

Although mHealth has been gaining in popularity for at least the past decade, before commercializing their mHealth products, developers must determine whether the product is subject to U.S. If so, developers must develop and execute on a regulatory strategy. The FDA’s General Approach to Regulating mHealth Products.

Development 104

Development Regulation Production Life Science 104

Pharmaceutical Technology

APRIL 25, 2023

sCFH is an engineered and improved version of complement factor H (CFH) that can fit into adeno-associated virus (AAV) vectors with solid expression and applications confirmed in cultured human cells in vitro, in addition to various preclinical animal models in vivo. The firm will also receive single-digit royalties on net sales.

In-Vivo 130

In-Vivo In-Vitro Sales Engineer 130

Scienmag

OCTOBER 24, 2021

Therefore, understanding the local invasion mechanism is warranted in developing more effective therapeutic approaches, and identifying markers that predict poor prognosis. Many diagnosed patients relapse, despite radical resection of the primary oral squamous cell carcinoma (OSCC) lesion.

In-Vitro 67

In-Vitro In-Vivo Development 67

XTalks

APRIL 14, 2022

Conventional in vitro and in vivo studies are used in the drug development pipeline. However, could there be another way for developing biomedical products using in silico technology? This involves the use of an individualized computer simulation for medical device or drug development. Want to learn more?

Trials 98

Trials In-Vivo In-Vitro Clinical Trials 98

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. It is expected to accelerate the development of CFT8919 in important international markets.

In-Vivo 130

In-Vivo Bioavailability In-Vitro Licensing 130

Scienmag

AUGUST 31, 2020

The project seeks to kickstart the development of an open access “Organoid Cell Atlas” By creating well-characterized in vitro […].

In-Vitro 98

In-Vitro Research Development Bioinformatics 98

Pharmaceutical Technology

MAY 12, 2023

Matinas said it developed this unique formulation to “handle the physical complexity and biological fragility of mRNA”. Matinas said it developed this unique formulation to “handle the physical complexity and biological fragility of mRNA”. Matinas announced the news in a May 10 statement.

Vaccination 130

Vaccination Vaccine In-Vivo In-Vitro 130

Pharmaceutical Technology

APRIL 12, 2023

FoundationOne CDx is a sequencing-based in vitro diagnostic device that can identify alterations in 324 genes from tumour samples. Repotrectinib has been developed to combat cancer resistance to existing therapies and exert consistent anti-tumor activity. The ROS1 gene is altered in approximately in 1-2% of lung cancer patients.

Genome 130

Genome Genomics In-Vitro Gene 130

XTalks

JUNE 27, 2022

Leading global medical technology company Becton Dickinson (BD) and Spain’s CerTest Biotec have announced they will be collaborating to develop a molecular diagnostic test for the detection of the monkeypox virus. Related: Monkeypox Case Reported in the US as Virus Spreads Across Europe and North America.

Development 83

Development In-Vitro Reagent Vaccination 83

Pharmaceutical Technology

MAY 31, 2023

ZNA-1041 is under clinical development by F. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases.

In-Vitro 130

In-Vitro Clinical Trials Clinical Trials Drugs 130

pharmaphorum

AUGUST 4, 2022

Training and development. Staff development and training programmes were largely on pause during the pandemic. Businesses need to ensure they prioritise the recruitment and development of staff to help ensure longevity and survival. Harness technology.

Development 98

Development In-Vitro Manufacturing Compliance 98

pharmaphorum

OCTOBER 4, 2022

Such non-device CDS are: (1) not intended to acquire, process, or analyse a medical image or a signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition system (Criterion 1); (2) intended for the purpose of displaying, analysing, or printing medical information about a patient or other medical information (e.g.

Development 105

Development Regulation Cosmetics Life Science 105

XTalks

JANUARY 15, 2021

Ortho Clinical Diagnostics received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its VITROS SARS-CoV-2 antigen test for detection of active COVID-19 infection. Related: COVID-19 Vaccine and Drug Development Coverage. active virus).

In-Vitro 105

In-Vitro Vaccination Vaccine Drugs 105

XTalks

JANUARY 21, 2025

TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

OCTOBER 16, 2020

This week’s round up features a digital solution for adapting clinical trials to ease the burden on the clinical research industry and an in vitro model that mimics the human airway epithelium using a newly developed technology platform. In vitro antiviral technology proves effective against SARS-CoV-2 in human airway infection model.

In-Vitro 52

In-Vitro Clinical Trials Clinical Trials Trials 52

Pharmaceutical Technology

NOVEMBER 4, 2022

The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise. The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise. at closing.

In-Vivo 130

In-Vivo In-Vitro Genetics Drugs 130

Pharmaceutical Technology

FEBRUARY 23, 2023

Innovation S-curve for artificial Intelligence in the pharmaceutical industry In-silico drug discovery is a key innovation area in artificial Intelligence Drug research starts with the discovery stage that involves in vivo and in vitro models to shortlist lead drug compounds.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Pharmaceutical Technology

JUNE 1, 2023

Pneumagen has raised £8m ($10 million) for the further development of its intranasal antiviral drug neumifil in Phase II studies for chronic obstructive pulmonary disease (COPD) patients suffering from virus-induced exacerbations. million) for the Phase II development of neumifil in January 2022. million ($4.75

In-Vitro 130

In-Vitro Engineer Protein Vaccination 130

Medical Xpress

APRIL 6, 2023

Fertility and in vitro fertilization (IVF) centers are receiving increasing numbers of infected patients. Since December 2022, the nationwide control policy on the COVID-19 epidemic has been changed in China. However, there is still a lack of high-quality evidence on the effects of the virus on human oocytes and early-stage embryos.

In-Vitro 71

In-Vitro Development 71

Pharmaceutical Technology

MAY 10, 2023

Under the two-year deal, both parties expect to develop new treatment methods for patients’ unmet AML and breast cancer needs at a reasonable price. The research teams will examine the use of CytoMed’s allogeneic gdTc on multiple AML and breast cancer subtypes in vitro and in vivo.

Gene Therapy 147

Gene Therapy In-Vivo In-Vitro Gene 147

Pharmaceutical Technology

FEBRUARY 1, 2023

The dual FLT-3 and Aurora kinase inhibitor EP0042 is being developed to treat AML patients who have developed FLT3 inhibitor resistance. Ellipses Pharma stated that the dual FLT3 inhibition and Aurora kinase demonstrated to overcome the acquired resistance to selectively inhibit FLT3 in vitro and in vivo.

FDA Approval 130

FDA Approval In-Vivo In-Vitro Trials 130